NASDAQ:SGEN - Seattle Genetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $172.38
  • Forecasted Upside: -12.46 %
  • Number of Analysts: 19
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
$196.92
▼ -3.74 (-1.86%)
1 month | 3 months | 12 months
Get New Seattle Genetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGEN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$172.38
▼ -12.46% Downside Potential
This price target is based on 19 analysts offering 12 month price targets for Seattle Genetics in the last 3 months. The average price target is $172.38, with a high forecast of $216.00 and a low forecast of $100.00. The average price target represents a -12.46% upside from the last price of $196.92.
Buy
The current consensus among 19 investment analysts is to buy stock in Seattle Genetics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/3/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/1/2019
  • 1 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/30/2019
  • 1 strong buy ratings
  • 11 buy ratings
  • 7 hold ratings
  • 0 sell ratings
1/28/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings
4/27/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 1 sell ratings
7/26/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 7 hold ratings
  • 1 sell ratings
9/24/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 1 sell ratings
10/24/2020

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/22/2020OppenheimerInitiated CoverageBuy$213.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/16/2020William BlairReiterated RatingBuyMedium
i
10/15/2020Bank of AmericaBoost Price TargetNeutral$180.00 ➝ $215.00Low
i
10/13/2020JMP SecuritiesBoost Price TargetPositive ➝ Outperform$200.00 ➝ $216.00Medium
i
Rating by Reni Benjamin at JMP Securities
10/12/2020SVB LeerinkBoost Price TargetOutperform$187.00 ➝ $204.00Medium
i
9/22/2020JMP SecuritiesBoost Price Target$185.00 ➝ $200.00Low
i
Rating by Reni Benjamin at JMP Securities
9/22/2020Stifel NicolausBoost Price TargetHold$145.00 ➝ $165.00Low
i
9/22/2020SVB LeerinkBoost Price TargetOutperform$185.00 ➝ $187.00Low
i
9/18/2020Needham & Company LLCInitiated CoverageBuy$188.00Low
i
Rating by Chad Messer at Needham & Company LLC
9/16/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
i
9/15/2020SVB LeerinkBoost Price TargetOutperform$173.00 ➝ $185.00Medium
i
9/15/2020Morgan StanleyBoost Price TargetEqual Weight$160.00 ➝ $167.00Medium
i
9/14/2020Royal Bank of CanadaBoost Price TargetOutperform$175.00 ➝ $191.00Medium
i
7/31/2020Morgan StanleyBoost Price TargetEqual Weight$149.00 ➝ $160.00High
i
7/31/2020SVB LeerinkBoost Price TargetOutperform$167.00 ➝ $173.00Low
i
7/31/2020HC WainwrightReiterated RatingBuy$175.00 ➝ $200.00Low
i
7/24/2020Piper SandlerDowngradeOverweight ➝ Neutral$155.00 ➝ $165.00Low
i
7/2/2020William BlairReiterated RatingBuyLow
i
6/30/2020BMO Capital MarketsBoost Price Target$174.00 ➝ $186.00High
i
Rating by George Farmer at BMO Capital Markets
6/30/2020SVB LeerinkBoost Price TargetOutperform$155.00 ➝ $167.00Low
i
6/30/2020Needham & Company LLCBoost Price TargetBuy$163.00 ➝ $188.00Low
i
6/26/2020OppenheimerBoost Price TargetPositive ➝ Outperform$175.00 ➝ $200.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/31/2020OppenheimerInitiated CoverageBuy$146.00 ➝ $175.00Medium
i
5/26/2020JMP SecuritiesInitiated CoverageOutperform$185.00High
i
5/26/2020Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
i
5/4/2020Morgan StanleyBoost Price TargetEqual Weight$111.00 ➝ $149.00High
i
Rating by Matthew Harrison at Morgan Stanley
5/3/2020BarclaysReiterated RatingNeutral ➝ HoldHigh
i
5/1/2020CfraBoost Price TargetSell$122.00 ➝ $129.00High
i
5/1/2020Stifel NicolausBoost Price TargetHold$120.00 ➝ $127.00High
i
5/1/2020Royal Bank of CanadaBoost Price TargetOutperform$148.00 ➝ $149.00High
i
5/1/2020SVB LeerinkBoost Price TargetOutperform$146.00 ➝ $155.00High
i
5/1/2020Needham & Company LLCBoost Price TargetBuy$157.00 ➝ $163.00High
i
5/1/2020HC WainwrightBoost Price TargetBuy$150.00 ➝ $175.00High
i
Rating by Andrew Fein at HC Wainwright
5/1/2020GuggenheimUpgradeNeutral ➝ BuyHigh
i
Rating by Michael Schmidt at Guggenheim
4/27/2020Piper SandlerBoost Price TargetOverweight$135.00 ➝ $155.00Low
i
4/20/2020BMO Capital MarketsBoost Price TargetOutperform$139.00 ➝ $154.00Medium
i
Rating by George Farmer at BMO Capital Markets
4/20/2020SVB LeerinkBoost Price TargetOutperform$138.00 ➝ $146.00Low
i
4/20/2020Stifel NicolausBoost Price TargetHold$103.00 ➝ $120.00Medium
i
4/20/2020OppenheimerBoost Price TargetOutperform$124.00 ➝ $146.00Low
i
4/20/2020Needham & Company LLCBoost Price TargetPositive ➝ Buy$144.00 ➝ $157.00Medium
i
Rating by Chad Messer at Needham & Company LLC
4/20/2020Royal Bank of CanadaBoost Price TargetOutperform$121.00 ➝ $147.00High
i
4/20/2020Piper SandlerBoost Price TargetOverweight$125.00 ➝ $135.00High
i
4/19/2020Royal Bank of CanadaReiterated RatingBuyHigh
i
4/15/2020Morgan StanleyBoost Price TargetEqual Weight$107.00 ➝ $111.00Medium
i
Rating by Matthew Harrison at Morgan Stanley
4/3/2020William BlairReiterated RatingBuyLow
i
Rating by Andy Hsieh at William Blair
3/3/2020William BlairReiterated RatingOutperformMedium
i
Rating by Andy Hsieh at William Blair
2/18/2020BarclaysDowngradeOverweight ➝ Equal Weight$124.00Medium
i
2/12/2020HC WainwrightReiterated RatingBuy$140.00 ➝ $150.00Low
i
Rating by Andrew Fein at HC Wainwright
2/11/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/11/2020Goldman Sachs GroupBoost Price TargetBuy$126.00 ➝ $165.00Low
i
Rating by Salveen Richter at Goldman Sachs Group Inc
2/7/2020Piper SandlerLower Price Target$125.00Low
i
2/7/2020William BlairReiterated RatingOutperformHigh
i
Rating by Andy Hsieh at William Blair
2/7/2020Needham & Company LLCReiterated RatingBuy$135.00High
i
Rating by Chad Messer at Needham & Company LLC
1/27/2020BMO Capital MarketsInitiated CoverageOutperform$139.00Medium
i
1/27/2020Royal Bank of CanadaReiterated RatingBuy$113.00Medium
i
1/17/2020Morgan StanleyLower Price TargetEqual Weight$123.00 ➝ $115.00Low
i
Rating by Matthew Harrison at Morgan Stanley
1/2/2020GuggenheimDowngradeBuy ➝ NeutralHigh
i
12/22/2019CowenReiterated RatingHold$100.00Medium
i
Rating by Boris Peaker at Cowen Inc
12/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$120.00 ➝ $130.00High
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
12/19/2019William BlairReiterated RatingBuyMedium
i
Rating by Andy Hsieh at William Blair
12/19/2019Stifel NicolausBoost Price Target$87.00 ➝ $101.00High
i
Rating by Stephen Willey at Stifel Nicolaus
12/13/2019William BlairReiterated RatingBuyLow
i
12/13/2019HC WainwrightReiterated RatingBuy$140.00Medium
i
Rating by Andrew Fein at HC Wainwright
12/12/2019OppenheimerBoost Price TargetOutperform$110.00 ➝ $124.00Low
i
12/12/2019Needham & Company LLCReiterated RatingBuy$130.00High
i
Rating by Chad Messer at Needham & Company LLC
12/10/2019Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$123.00Low
i
12/3/2019Bank of AmericaInitiated CoverageNeutral$125.00High
i
Rating by Tazeen Ahmad at Bank of America Co.
10/31/2019BarclaysReiterated RatingBuy$117.00Low
i
10/30/2019Piper Jaffray CompaniesBoost Price TargetOverweight$120.00Medium
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
10/25/2019William BlairReiterated RatingBuyLow
i
Rating by Andy Hsieh at William Blair
10/22/2019Royal Bank of CanadaBoost Price TargetOutperform$80.00 ➝ $109.00Low
i
10/22/2019Deutsche Bank AktiengesellschaftBoost Price TargetHold$88.00 ➝ $95.00Low
i
10/22/2019SVB LeerinkBoost Price TargetOutperform ➝ Positive$102.00 ➝ $120.00Medium
i
Rating by Andrew Berens at SVB Leerink LLC
10/22/2019OppenheimerBoost Price TargetOutperform$92.00 ➝ $110.00Medium
i
10/22/2019GuggenheimBoost Price TargetBuy ➝ Outperform$95.00 ➝ $120.00Low
i
10/22/2019Bank of AmericaBoost Price TargetUnderperform$58.00 ➝ $83.00Low
i
Rating by Tazeen Ahmad at Bank of America Co.
10/22/2019HC WainwrightReiterated RatingBuy$98.00 ➝ $140.00Medium
i
10/21/2019Piper Jaffray CompaniesSet Price TargetBuy$95.00Low
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
10/21/2019Needham & Company LLCSet Price TargetBuy$121.00Low
i
Rating by Chad Messer at Needham & Company LLC
10/21/2019CowenSet Price TargetHold$80.00Low
i
Rating by Boris Peaker at Cowen Inc
10/21/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/2/2019Deutsche Bank AktiengesellschaftBoost Price TargetHold$79.00 ➝ $88.00Low
i
10/1/2019OppenheimerBoost Price TargetOutperform$82.00 ➝ $92.00Low
i
9/30/2019Needham & Company LLCSet Price TargetBuy$81.00Low
i
Rating by Chad Messer at Needham & Company LLC
9/30/2019Stifel NicolausSet Price TargetHold$74.00Low
i
Rating by Stephen Willey at Stifel Nicolaus
9/30/2019SVB LeerinkSet Price TargetBuy$102.00Low
i
Rating by Andrew Berens at SVB Leerink LLC
9/30/2019CowenSet Price TargetHold$80.00High
i
9/29/2019Piper Jaffray CompaniesBoost Price TargetOverweight$75.00 ➝ $95.00High
i
9/27/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
9/27/2019Bank of AmericaSet Price TargetSell$58.00Low
i
Rating by Tazeen Ahmad at Bank of America Co.
9/27/2019Goldman Sachs GroupUpgradeNeutral ➝ Buy$78.00 ➝ $100.00High
i
9/12/2019OppenheimerUpgradeMarket Perform ➝ Outperform$77.00 ➝ $82.00Medium
i
8/26/2019BTIG ResearchInitiated CoverageNeutralLow
i
7/19/2019William BlairReiterated RatingBuyLow
i
Rating by Andy Hsieh at William Blair
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$79.00Medium
i
7/17/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$64.00 ➝ $75.00High
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
6/5/2019William BlairReiterated RatingBuyLow
i
4/28/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
4/26/2019HC WainwrightReiterated RatingBuyMedium
i
4/10/2019Stifel NicolausInitiated CoverageHold$70.00Medium
i
4/5/2019Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$89.00 ➝ $90.00Low
i
3/28/2019Piper Jaffray CompaniesReiterated RatingHoldMedium
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
3/27/2019Berenberg BankInitiated CoverageBuy ➝ Buy$95.00Medium
i
3/25/2019William BlairReiterated RatingOutperformLow
i
2/8/2019HC WainwrightReiterated RatingBuy$98.00High
i
2/7/2019Piper Jaffray CompaniesLower Price TargetNeutral$64.00High
i
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/26/2018BarclaysLower Price TargetOverweight ➝ Overweight$95.00 ➝ $90.00High
i
10/26/2018Needham & Company LLCLower Price TargetBuy$73.00High
i
10/26/2018Bank of AmericaDowngradeNeutral ➝ UnderperformHigh
i
10/26/2018HC WainwrightReiterated RatingBuy$98.00High
i
10/25/2018Piper Jaffray CompaniesLower Price TargetNeutral$66.00High
i
10/3/2018BarclaysBoost Price TargetPositive ➝ Overweight$80.00 ➝ $95.00Medium
i
10/2/2018Royal Bank of CanadaBoost Price TargetOutperform$98.00Low
i
9/26/2018JPMorgan Chase & Co.Reiterated RatingBuy$85.00Low
i
9/24/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$101.00Medium
i
Rating by A. Berens at SVB Leerink LLC
9/17/2018GuggenheimInitiated CoverageBuyMedium
i
9/7/2018Piper Jaffray CompaniesReiterated RatingNeutral ➝ NeutralLow
i
7/30/2018Needham & Company LLCBoost Price TargetBuy$74.00 ➝ $79.00High
i
7/27/2018SunTrust BanksSet Price TargetBuy$81.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
7/27/2018BarclaysReiterated RatingBuy$80.00Low
i
7/27/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$66.00 ➝ $77.00High
i
7/27/2018Royal Bank of CanadaReiterated RatingBuy$75.00High
i
7/27/2018HC WainwrightReiterated RatingBuy$77.00 ➝ $98.00High
i
7/12/2018HC WainwrightReiterated RatingBuy$77.00Low
i
6/11/2018SunTrust BanksUpgradeHold ➝ Buy$60.00 ➝ $80.00Medium
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
6/5/2018HC WainwrightReiterated RatingBuyMedium
i
4/26/2018Cantor FitzgeraldSet Price TargetHold$50.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
3/21/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$69.00 ➝ $67.00Low
i
3/20/2018Cantor FitzgeraldSet Price TargetHold$50.00Medium
i
Rating by Mara Goldstein at Cantor Fitzgerald
3/20/2018Royal Bank of CanadaReiterated RatingBuy$73.00Medium
i
3/20/2018BarclaysInitiated CoverageOverweight ➝ Overweight$74.00High
i
3/13/2018CowenReiterated RatingHoldLow
i
2/14/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$60.00Low
i
2/7/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$70.00 ➝ $68.00Low
i
2/7/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00 ➝ $74.00High
i
2/7/2018SunTrust BanksReiterated RatingHold$60.00High
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
2/7/2018HC WainwrightReiterated RatingBuyHigh
i
Rating by A. Fein at HC Wainwright
2/1/2018HC WainwrightReiterated RatingBuy$75.00High
i
Rating by A. Fein at HC Wainwright
1/9/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
i
1/8/2018Cantor FitzgeraldSet Price TargetHold$50.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
1/2/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/12/2017Cantor FitzgeraldSet Price TargetHold$50.00Medium
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/11/2017CowenReiterated RatingHold$54.00Low
i
Rating by Boris Peaker at Cowen Inc
12/7/2017OppenheimerReiterated RatingHoldMedium
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/13/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$68.00 ➝ $69.00N/A
i
10/31/2017Morgan StanleyBoost Price TargetOverweight$64.00 ➝ $69.00N/A
i
10/30/2017JPMorgan Chase & Co.Boost Price TargetNeutral$55.00 ➝ $60.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/29/2017CowenReiterated RatingHoldN/A
i
Rating by Boris Peaker at Cowen Inc
10/27/2017SunTrust BanksSet Price TargetHold$52.00N/A
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
10/27/2017HC WainwrightReiterated RatingBuy$75.00N/A
i
Rating by A. Fein at HC Wainwright
10/27/2017Bank of AmericaUpgradeUnderperform ➝ NeutralN/A
i
10/26/2017Jefferies Financial GroupReiterated RatingBuy$53.00N/A
i
10/23/2017GuggenheimReiterated RatingBuy ➝ Buy$72.00N/A
i
10/20/2017BarclaysUpgradeEqual Weight ➝ Overweight$60.00 ➝ $70.00N/A
i
10/16/2017BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$55.00 ➝ $60.00N/A
i
10/10/2017Cantor FitzgeraldSet Price TargetHold$46.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
10/10/2017OppenheimerInitiated CoverageHoldN/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
10/6/2017Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$64.00N/A
i
10/4/2017SunTrust BanksReiterated RatingHold$45.00N/A
i
10/2/2017Cantor FitzgeraldSet Price TargetHold$46.00Medium
i
Rating by Mara Goldstein at Cantor Fitzgerald
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$58.00Medium
i
9/14/2017Jefferies Financial GroupReiterated RatingBuy$53.00Low
i
9/8/2017OppenheimerReiterated RatingHoldLow
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
8/29/2017Cantor FitzgeraldReiterated RatingHoldMedium
i
Rating by Mara Goldstein at Cantor Fitzgerald
8/16/2017Cantor FitzgeraldSet Price TargetHold$46.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
7/28/2017CowenReiterated RatingHold$54.00High
i
Rating by Boris Peaker at Cowen Inc
7/27/2017Jefferies Financial GroupReiterated RatingBuy$53.00High
i
6/27/2017JPMorgan Chase & Co.Reiterated RatingNeutralHigh
i
6/27/2017Piper Jaffray CompaniesReiterated RatingNeutral$48.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
6/26/2017William BlairReiterated RatingOutperformHigh
i
Rating by A. Hsieh at William Blair
6/26/2017Cantor FitzgeraldReiterated RatingHold$43.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
6/23/2017BarclaysReiterated RatingHoldMedium
i
6/21/2017Morgan StanleyLower Price TargetOverweight$70.00 ➝ $64.00Medium
i
6/20/2017JPMorgan Chase & Co.Reiterated RatingNeutral$58.00 ➝ $55.00Medium
i
6/20/2017Needham & Company LLCReiterated RatingBuy$72.00Low
i
6/19/2017Cantor FitzgeraldSet Price TargetHold$43.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
6/19/2017CowenReiterated RatingHold$61.00 ➝ $54.00High
i
Rating by Boris Peaker at Cowen Inc
6/15/2017OppenheimerReiterated RatingHoldMedium
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
6/13/2017JPMorgan Chase & Co.Reiterated RatingHold$58.00Low
i
6/6/2017CowenSet Price TargetHold$61.00Low
i
Rating by Boris Peaker at Cowen Inc
6/3/2017OppenheimerReiterated RatingHoldLow
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
4/28/2017HC WainwrightBoost Price TargetBuy$65.00 ➝ $75.00Low
i
Rating by Andrew Fein at HC Wainwright
4/7/2017SVB LeerinkBoost Price TargetOutperform$70.00 ➝ $74.00Medium
i
3/16/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformLow
i
3/16/2017OppenheimerInitiated CoverageMarket PerformLow
i
3/6/2017Cantor FitzgeraldReiterated RatingHold$43.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
2/16/2017Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
i
2/13/2017Credit Suisse GroupBoost Price TargetNeutral$62.00 ➝ $66.00N/A
i
2/10/2017HC WainwrightReiterated RatingBuy$65.00N/A
i
Rating by Andrew Fein at HC Wainwright
2/10/2017Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
i
1/5/2017Royal Bank of CanadaSet Price TargetBuy$80.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
1/5/2017Maxim GroupReiterated RatingReduceN/A
i
12/28/2016Credit Suisse GroupReiterated RatingNeutral$70.00 ➝ $60.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
12/28/2016Cantor FitzgeraldReiterated RatingNeutral$43.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/27/2016Needham & Company LLCReiterated RatingHold$72.00N/A
i
12/12/2016CowenReiterated RatingHold$47.00N/A
i
12/12/2016Credit Suisse GroupDowngradeOutperform ➝ Neutral$53.00 ➝ $70.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
12/9/2016Cantor FitzgeraldSet Price TargetHold$43.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/6/2016Royal Bank of CanadaBoost Price TargetOutperform$62.00 ➝ $72.00N/A
i
11/29/2016BarclaysDowngradeOverweight ➝ Equal Weight$53.00 ➝ $70.00N/A
i
Rating by Jonathan Eckard at Barclays PLC
10/31/2016JPMorgan Chase & Co.Reiterated RatingHold$43.00N/A
i
10/30/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
10/24/2016SVB LeerinkReiterated RatingOutperform$62.00N/A
i
10/10/2016Royal Bank of CanadaReiterated RatingOutperform$55.00 ➝ $62.00N/A
i
10/10/2016SVB LeerinkReiterated RatingOutperform$62.00N/A
i
10/10/2016Royal Bank of CanadaBoost Price TargetOutperform$55.00 ➝ $62.00N/A
i
9/16/2016SVB LeerinkReiterated RatingBuy$62.00N/A
i
9/16/2016Goldman Sachs GroupDowngradeNeutral ➝ SellN/A
i
9/15/2016Goldman Sachs GroupUpgradeSell ➝ Neutral$30.00 ➝ $47.00N/A
i
9/7/2016Morgan StanleyInitiated CoverageOverweight$60.00N/A
i
8/1/2016SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $52.00N/A
i
7/27/2016Royal Bank of CanadaReiterated RatingOutperformN/A
i
7/27/2016BarclaysBoost Price TargetOverweight$48.00 ➝ $53.00N/A
i
7/27/2016SunTrust BanksBoost Price TargetNeutral$34.00 ➝ $38.00N/A
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
7/27/2016Cantor FitzgeraldDowngradeBuy ➝ Hold$43.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
6/29/2016Needham & Company LLCReiterated RatingBuy$60.00 ➝ $72.00N/A
i
6/20/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
6/13/2016HC WainwrightReiterated RatingBuy$65.00N/A
i
Rating by Andrew Fein at HC Wainwright
6/8/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
6/8/2016Cantor FitzgeraldReiterated RatingBuy$43.00N/A
i
5/19/2016CowenReiterated RatingHoldN/A
i
Rating by Boris Peaker at Cowen Inc
4/30/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
4/29/2016Credit Suisse GroupReiterated RatingBuy$51.00N/A
i
Rating by Jeremiah Shepard at Credit Suisse Group AG
4/17/2016CowenReiterated RatingHoldN/A
i
Rating by Boris Peaker at Cowen Inc
3/2/2016SunTrust BanksInitiated CoverageNeutral$34.00N/A
i
2/11/2016OppenheimerReiterated RatingMarket PerformN/A
i
2/11/2016CowenReiterated RatingMarket PerformN/A
i
2/11/2016HC WainwrightReiterated RatingBuy$65.00N/A
i
2/10/2016SVB LeerinkLower Price TargetOutperform$56.00 ➝ $52.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
2/10/2016BarclaysLower Price TargetOverweight$51.00 ➝ $50.00N/A
i
2/10/2016Piper Jaffray CompaniesLower Price TargetNeutral$44.00 ➝ $33.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
2/10/2016JPMorgan Chase & Co.Lower Price TargetNeutral$45.00 ➝ $43.00N/A
i
2/10/2016Cantor FitzgeraldUpgradeHold ➝ Buy$38.00N/A
i
Rating by M. Goldstein at Cantor Fitzgerald
2/4/2016BarclaysInitiated CoverageOverweight$51.00N/A
i
1/20/2016Credit Suisse GroupInitiated CoverageOutperform$52.00N/A
i
1/13/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
12/8/2015Needham & Company LLCReiterated RatingBuy$60.00N/A
i
Rating by Chad Messer at Needham & Company LLC
11/18/2015Goldman Sachs GroupInitiated CoverageSell$33.00N/A
i
10/30/2015Needham & Company LLCReiterated RatingBuy$60.00N/A
i
10/30/2015Piper Jaffray CompaniesUpgradeUnderweight ➝ Neutral$30.00 ➝ $44.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
(Data available from 10/24/2015 forward)
Seattle Genetics logo
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $196.92
$196.23
$202.26

50 Day Range

MA: $182.81
$145.95
$211.93

52 Week Range

Now: $196.92
$90.57
$213.94

Volume

479,621 shs

Average Volume

864,268 shs

Market Capitalization

$34.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13